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Abstract
Background: Pyrethroids are neurotoxic pesticides that interact with membrane bound ion channels in neurons and
disrupt nerve function. The purpose of this study was to characterize and explore changes in gene expression that occur
in the rat frontal cortex, an area of CNS affected by pyrethroids, following an acute low-dose exposure.
Results: Rats were acutely exposed to either deltamethrin (0.3 – 3 mg/kg) or permethrin (1 – 100 mg/kg) followed by
collection of cortical tissue at 6 hours. The doses used range from those that cause minimal signs of intoxication at the
behavioral level to doses well below apparent no effect levels in the whole animal. A statistical framework based on
parallel linear (SAM) and isotonic regression (PIR) methods identified 95 and 53 probe sets as dose-responsive. The PIR
analysis was most sensitive for detecting transcripts with changes in expression at the NOAEL dose. A sub-set of genes
(Camk1g, Ddc, Gpd3, c-fos and Egr1) was then confirmed by qRT-PCR and examined in a time course study. Changes in
mRNA levels were typically less than 3-fold in magnitude across all components of the study. The responses observed
are consistent with pyrethroids producing increased neuronal excitation in the cortex following a low-dose in vivo
exposure. In addition, Significance Analysis of Function and Expression (SAFE) identified significantly enriched gene
categories common for both pyrethroids, including some relating to branching morphogenesis. Exposure of primary
cortical cell cultures to both compounds resulted in an increase (~25%) in the number of neurite branch points,
supporting the results of the SAFE analysis.
Conclusion: In the present study, pyrethroids induced changes in gene expression in the frontal cortex near the
threshold for decreases in ambulatory motor activity in vivo. The penalized regression methods performed similarly in
detecting dose-dependent changes in gene transcription. Finally, SAFE analysis of gene expression data identified
branching morphogenesis as a biological process sensitive to pyrethroids and subsequent in vitro experiments confirmed
this predicted effect. The novel findings regarding pyrethroid effects on branching morphogenesis indicate these
compounds may act as developmental neurotoxicants that affect normal neuronal morphology.
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Pyrethroid insecticides represent a significant percentage
of the world insecticide market [1]. This usage results in
an increased potential for human exposure. Pyrethroid
residues have been detected in sediments from agricul-
tural run-off [2], residential dust samples [3] and child-
care centers [4]. Pyrethroid metabolites have also been
detected in human urine [5]. A major research focus for
pyrethroids is determining if compounds belonging to
this chemical class act through the same or similar mech-
anisms-of-action to produce similar adverse health out-
comes [6].
Pyrethroids disrupt nervous system function by interact-
ing with membrane bound ion channels and altering their
normal gating kinetics [7]. The primary molecular targets
of pyrethroids are neuronal voltage-sensitive sodium
channels (VSSCs) [6]. Prolongation of whole-cell Na+ cur-
rents has been observed in a variety of cultured nervous
system tissues exposed to pyrethroids [8-10]. Further-
more, in vitro studies utilizing heterologous expression
systems have demonstrated that pyrethroids increase
sodium current through VSSC isoforms (Nav1.2, Nav1.4 &
Nav1.8), although the complete complement of mamma-
lian VSSCs have not been examined for pyrethroid sensi-
tivity [11-13]. Pyrethroids may also alter the gating
kinetics of both neuronal voltage-sensitive Ca+2 (VGCCs)
and voltage-sensitive Cl- channels [14-17]. Isoforms of all
of the aforementioned molecular targets are expressed in
the plasma membrane of mammalian neuronal cells.
Pyrethroids affect nervous system function by producing
hyperexcitability in neurons and changing neuronal firing
rates [18-21]. Acute manifestations of neurotoxicity on
mammalian and insect species result from increased neu-
ronal hyperexcitability driven by the actions of pyre-
throids at their molecular target sites, primarily VSSCs
[21]. Under normal conditions, neuronal excitation at the
membrane results in the activation of intracellular signal-
ing pathways that control the induction of gene expres-
sion [22]. In some cases, these transcriptional responses
led to persistent adaptive changes in cellular functions
(i.e. neuronal plasticity) [23,24]. Neuroactive chemicals
that alter firing patterns or disrupt neurotransmission trig-
ger the induction of unique groups of gene transcripts
which may in turn impact neuronal function [25-27].
While alterations in neuronal excitability are critical
events in the toxiciological mechanism-of-action for pyre-
throids, the impact of pyrethroid-induced neuronal
hyperexcitability on intracellular signaling pathways and
inducible gene-regulatory networks is unknown.
The neuronal substrates that mediate acute pyrethroid
neurotoxicity in vivo are unknown and it is likely that mul-
tiple brain regions are involved. However, previous stud-
ies have demonstrated rapid accumulation of pyrethroids
in the cortex following an acute oral dose, disruption of
cortical neuronal firing patterns both in vivo and in vitro,
and induction of gene products known to be upregulated
following neuronal excitation [18,28-32]. Presently, the
cortex is one of the few brain regions where pharmacoki-
netic, electrophysiological and biochemical data are avail-
able for pyrethroids. These data provide a significant
weight of evidence that this brain region may be sensitive
to acute pyrethroid exposures. The present study aims to
characterize the effects of acute pyrethroid exposure on
gene expression in the cortex.
In the present study Affymetrix GeneChip® microarrays
were used to characterize the global transcriptional
response of rat frontal cortex following an acute oral expo-
sure to two model pyrethroids: permethrin and deltame-
thrin. The dose ranges used included doses that cause
minimal neurotoxic signs, as well as doses below apparent
'no adverse effect levels' (NOAEL) in in vivo behavioral
studies of motor function [33]. Differences in potency
between the two compounds are due to differing pharma-
cokinetic profiles and likely varying pharmacodynamic
activities [12,28,30,32]. In the present study, low doses
were used to minimize any potential transcriptional
changes which may be due solely to excessive systemic
toxicity at high pyrethroid doses. Primary goals of this
study were to: 1) to use a previously established linear
regression (SAM) and a novel isotonic (PIR) regression
method [34,35] as discovery and prioritization tools for
identification of dose-dependent changes in gene tran-
scription, and 2) to compare the performance of these
methods, 3) to confirm pyrethroid-sensitive transcrip-
tional changes in a selected sub-set of genes using qRT-
PCR, 4) to examine the time course of these changes and
5) to utilize functional category level analysis (SAFE) [36]
to identify pyrethroid sensitive cellular processes.
Dose-dependent changes in the transcription of several
genes (Camk1g, Ddc, Gpd3, c-fos and Egr1) were discov-
ered and successfully confirmed. Data from qRT-PCR
experiments demonstrated clear qualitative similarities in
the transcriptional response produced by both com-
pounds. In addition, based on the SAFE analysis results,
the hypothesis that pyrethroids can affect neuronal
branching morphology was tested in an in vitro model of
cortical neuron development. An increase (~25%) in the
number of neuronal branch points was observed. This
may represent a novel aspect of pyrethroid neurotoxicity
that to date has not been examined.
Methods
Chemicals
Permethrin (92.0% purity, isomer composition: 40% cis,
60% trans, 1:1 ratio of 1R & 1S) and deltamethrin (98.9%Page 2 of 23
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erously donated by FMC Corporation (Philadelphia, PA)
and Bayer Cropscience (Research Triangle Park, NC),
respectively. Pyrethroids were dissolved in corn oil
(Sigma-Aldrich, St. Louis, MO) at 1, 10, 40 & 100 mg/mL
permethrin and 0.3, 1 & 3 mg/mL deltamethrin. Dosing
volume was 1 mL/kg.
Animal Care and Treatment
Male Long-Evans rats (49–62 days of age) were obtained
from Charles River Laboratories (Wilmington, MA) Hous-
ing conditions were identical to those used in Wolansky et
al. (2006) [33]. The facility was approved by the American
Association for Accreditation of Laboratory Animal Care
(AAALAC) and all experimental procedures were
approved in advance by the US EPA, NHEERL Animal
Care and Use Committee.
Four cohorts of animals were used in this study (Table 1).
Cohort 1 was used for preliminary data collection to dem-
onstrate that the selected doses of the two compounds
would alter gene transcription. Cohort 2 replicated these
findings and expanded group sizes. Cohorts 1 & 2 were
combined for microarray data analyses. Cohort 3 was
examined exclusively by quantitative real-time RT-PCR
(qRT-PCR). These dose-response cohorts (#1,2,3) were
exposed on separate days. All dosing occurred between
06:30 and 07:00 hours, counterbalanced across time of
day, and the last test subject euthanized before 18:00
hours. Cohort 4 was used in qRT-PCR time course studies
and dosed with 3 mg/kg deltamethrin, 100 mg/kg per-
methrin or vehicle. Each time point contained pyrethroid-
treated and time-matched vehicle controls and all test
subjects were dosed and euthanized between 07:30 &
17:30 hours. In all cohorts, test subjects were removed
from the colony suite 1 h prior to dosing and allowed to
acclimate in a quiet holding room maintained under sim-
ilar environmental conditions. Subjects were adminis-
tered a single oral dose of test compound by gavage and
allowed to recover in their home cage prior to euthanasia
at 6 h (dose-response studies) or 1, 3, 6 or 9 h (time course
studies). Subjects were removed to an adjoining suite with
a separate HVAC system for euthanasia by decapitation.
Whole brains were rapidly removed onto a cold plate
(4°C). Frontal cortex was dissected and frozen on a bed of
dry ice in less than 3 minutes and then stored at -80°C
until use.
RNA Extraction
Cortical samples were homogenized in 1 mL of TRI Rea-
gent (Molecular Research Center, Inc., Cincinnati, OH)
per 50–100 mg of tissue using a Polytron® PT-K homoge-
nizer (Kinematica, Lucerne, Switzerland) and total RNA
was isolated per manufacturer's instructions. Total RNA
pellets suspended in DEPC-treated H2O were then subject
to DNase I treatment and re-extracted with acid:phenol
chloroform, pH = 4.7 (Ambion Inc., Austin, TX) and chlo-
roform according to manufacturer's protocol and re-sus-
pended in DEPC-treated H2O until use. The total RNA
concentration of each sample was determined (absorb-
ance @ 260 nm) on a Beckman-Coulter DU® 800 spectro-
photometer (Fullerton, CA) and adjusted to 1.0 μg/μL
prior to sample storage at -80°C. The ratio of absorbance
values at 260 nm and 280 nm (Ab 260/280) was used to
assess purity of total RNA samples and a cut-off of > 1.6
was used (greater than 85% of the samples were > 1.7).
Preliminary PCR experiments using primers for rat β-actin
genomic DNA (outlined in [37]) demonstrated that the
above protocol adequately prevents genomic DNA con-
tamination of total RNA samples (data not shown). RNA
integrity of each sample was determined using an Agilent
2100 Bioanalyzer and RNA 6000 Nano LabChip Kit
Table 1: Group sizes of cohorts used in this study.
Permethrin Deltamethrin
Dose (mg/kg): Vehicle 1.0 10.0 40.0 100.0 0.3 1.0 3.0
EDL: Control < NOAEL NOAEL ED30 ED50 < NOAEL NOAEL ED30
Microarray Dose Response a
Cohort 1 6 3 3 3 3 3 3
Cohort 2 6 5 5 5 5 5 5
qRT-PCR Dose-Response b
Cohort 3 7 7 7 7 7
7 7 7 7
qRT-PCR Time Course c
Cohort 4 84 84
84 84
a Microarray data from Cohorts 1 & 2 were combined (n = 8/treatment group) with control values from cohorts 1 & 2 (n = 12) for dose-response 
analysis of permethrin and deltamethrin mediated effects, respectively. b Test animals in Cohort 3 were split into two dose-response studies for 
permethrin and deltamethrin, respectively, for qRT-PCR confirmation of gene expression changes observed during the microarray study. c Test 
animals in Cohort 4 were used for qRT-PCR time course studies. Four time points (1,3,6,9 hours: n = 8/treatment group) per compound with time 
matched controls (n = 8/control group). NOAEL = no observable adverse effect level; < NOAEL = less than no observable adverse effect level.Page 3 of 23
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instructions. All samples used in microarray and qRT-PCR
experiments had a RNA Integrity Number (RIN) > 8.0
(data not shown). Aliquots of each RNA sample (1 μg/μL
for microarray hybridization or 25 ng/μL for qRT-PCR
assays) were stored at -80°C until use.
Microarray sample preparation and data collection
All protocols for microarray sample preparation (except
total RNA extraction, as above), Affymetrix Rat Genome
230 2.0 GeneChip® hybridization, array scanning and data
collection were performed by Expression Analysis, Inc.,
(Durham, NC) according to standard Affymetrix proto-
cols. Synthesis and clean-up of biotin-labeled cRNA was
performed using a BioArray™ High Yield™ RNA transcript
labeling kit (Enzo Life Sciences, Farmingdale, NY) and
Qiagen RNeasy spin columns (Spoorstraat, Netherlands),
respectively, according to manufacturer's instructions.
Hybridizations were performed in an Affymetrix Hybridi-
zation Oven 640. Washes were performed on an Affyme-
trix Fluidics Station 450 using the EukGE-WS2v4-450
fluidics script. GeneChips® were scanned using an Affyme-
trix GeneChip® 3000 Scanner with the GCOS v1.2 soft-
ware package. Target intensity was set to a value of 500
with all other scanning parameters set at the factory
defaults. The 3'/5' ratios for GAPDH and β-actin internal
controls genes ranged between 0.93 – 1.11 and 1.2 – 2.01,
respectively for all samples, indicating that degradation of
RNA did not occur. The intensity of hybridization controls
(BioB, BioC, BioD and Cre) increased linearly on all arrays.
Gene expression profiles for this experiment have been
archived in the NCBI Gene Expression Omnibus (GEO)
repository with the series accession number GSE7955.
Microarray Data Analysis
Expression summaries were calculated using RMAExpress©
v4.7 (University of California at Berkeley). Consistent
with previous reports, Robust Multiarray Average (RMA)
[38] provided less within group variation in expression
summary values as compared to GeneChip® Operating
Software v1.2 (GCOS) [39] (see Additional file 1).
Analysis of dose-response relationships were performed
using Significance Analysis of Microarrays (SAM, version
2.21) [34], with the quantitative/linear regression mode-
ling component [40]. In addition to identifying dose-
responsive genes, SAM provides permutation-based esti-
mates of the false-discovery rate (FDR) associated with
lists of genes for which the null hypothesis is rejected. The
SAM statistic (di) penalizes lowly expressed genes, and is
most powerful when the dose-response function is nearly
linear in the range examined. To potentially increase
power and account for non-linearity in dose-response
relationships, the SAM analyses were supplemented by
penalized isotonic regression (PIR) according to the
method of Hu et al. (2005) [35] which was specifically
designed for microarray analysis. Similar to SAM, PIR
penalizes lowly expressed genes and provides a permuta-
tion-based estimate of the false discovery rate. In contrast
to SAM, PIR allows for the dose-response relationship to
be nonlinear, but assumes the relationship is increasing or
decreasing as a function of increasing dose, and not the
reverse direction. This method results in a score (the Mi-
statistic) for each probe set that quantifies the evidence for
an increasing or decreasing dose-response relationship.
To insure that the rigorously conservative, permutation-
based approaches for controlling Type I error did not
exclude true positive probe sets with dose-dependent
increases or decreases in expression, an additional analy-
sis was conducted with each regression model. Empirical
p-values from the PIR analysis or SAM analysis were used
to filter out probe sets with no apparent dose-related
changes in expression (threshold p-value < 0.01). The
reduced group of probe sets were then analyzed using a
one-way analysis of variance (ANOVA) followed by a Ben-
jamini-Hochberg correction for control of multiple com-
parisons. Dose was used as the independent factor. Probe
sets meeting the Benjamini-Hochberg correction at FDR <
0.05 were included in the gene lists of interest for each
compound, analysis of dose thresholds for transcriptional
changes and the comparison of effects between com-
pounds. For probe sets that passed the one-way ANOVA
significance threshold, a post-hoc Dunnett's multiple-
comparison mean contrast test was performed comparing
the means of the respective dose groups to the mean of the
control group [41]. Regression analyses were performed
using R© version 2.3.0 statistical computing analysis soft-
ware. Dunnett's tests were performed using SAS v8.1 (SAS
Institute, Inc., Cary, NC).
Quantitative real-time RT-PCR
In selecting candidates for qRT-PCR confirmation, prefer-
ence was given to probe sets highly ranked by the penal-
ized regression methods and corresponding to transcripts
with known protein-coding RefSeq accession numbers
(Tables 2 &3). qRT-PCR for each transcript of interest was
performed using TaqMan® One-Step RT-PCR Master Mix
Reagent Kits and TaqMan® Gene Expression Assays on an
ABI 7900HT Sequence Detection System (Applied Biosys-
tems, Foster City, CA) according to manufacturer's
instructions and using a 384 well plate format. Each sam-
ple was measured in triplicate for each transcript of inter-
est and an internal reference gene. Reaction plates were
maintained at 5°C during the loading procedure. Reac-
tions were incubated at 48°C for 45 min followed by
incubation at 95°C for 10 min and 40 cycles of 94°C for
25 sec followed by 60°C for 1 min. qRT-PCR assays were
designed via the Applied Biosystems (ABI) primer/probe
selection algorithm and bioinformatics pipeline [42].Page 4 of 23
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previously described using a serial dilution of pooled total
RNA from rat frontal cortex [43]. Assay identification
numbers, context sequences, amplicon lengths and calcu-
lated amplification efficiencies are listed in Additional file
2.
qRT-PCR data from deltamethrin and permethrin dose-
response and time course studies were analyzed according
to the 2-ΔΔCT method as described by Livak and Schmittgen
(2001) [44]. β-actin expression did not change as a func-
tion of time or dose for either compound (data not
shown) and was used at the internal reference for all 2-ΔΔCT
calculations. Data are expressed as 2-ΔΔCT ± standard error
(SE) which is an approximation of fold-change from the
calibrator group (i.e. vehicle control). For dose-response
studies (Table 4), the mean ΔΔCT of vehicle treated con-
trols were used as the 2-ΔΔCT calibrator [44]. For time
course studies, the mean ΔΔCT of vehicle treated controls
were used as the 2-ΔΔCT calibrator within each time-
matched treatment group.
Data from Wolansky et al. (2006) [33] were used to assign
equipotent dose-levels (EDL) to the administered doses
used in the present study to provide a comparative dose-
metric between the two test compounds (see Table 1). Sta-
tistical analysis of qRT-PCR dose response data was per-
formed using a two-way ANOVA with compound and
Table 2: Probe sets identified as dose-responsive for deltamethrin.
Linear Regression (SAM) Isotonic Regression (PIR) ANOVA
Affymetrix Probe Set I.D. Gene Symbol di p-value q-value Mi p-value q-value p-value
1371363_at Gpd1** 5.63 0.0000 0.00 2.34 0.0000 0.24 0.0032
1388901_at Fkbp51** 5.46 0.0000 0.00 2.21 0.0000 0.42 0.0051
1367577_at Hsp27** 4.60 0.0001 0.00 1.90 0.0002 0.97 0.0195
1369560_at Gpd1** 4.53 0.0001 0.00 1.91 0.0002 1.00 0.0134
1368064_a_at Ddc** -4.35 0.0001 0.14 -1.95 0.0002 1.00 0.0195
1391229_at Camk1g** 4.22 0.0002 0.00 2.11 0.0000 0.51 0.0063
1380611_at Fkbp51** 3.90 0.0004 0.11 1.62 0.0012 1.00 0.0276
1369303_at Crh 3.62 0.0009 0.11 1.73 0.0006 1.00 0.0276
1388271_at LOC689415 3.48 0.0013 0.19 1.44 0.0037 1.00 0.0300
1370989_at Ret 3.38 0.0017 0.19 1.49 0.0028 1.00 0.0300
1370026_at Cryab 3.28 0.0022 0.29 1.46 0.0032 1.00 0.0364
1374626_at Lrg1 3.23 0.0025 0.33 1.45 0.0036 1.00 0.0323
1376709_at Slc39a8 -3.07 0.0038 0.14 -1.49 0.0026 1.00 0.0364
1368650_at Klf10 -3.07 0.0038 0.14 -1.30 0.0077 1.00 0.0356
1380329_at Tmem10 -3.03 0.0041 0.14 -1.28 0.0086 1.00 0.0496
1372564_at Ets2 3.03 0.0042 0.51 1.41 0.0045 1.00 0.0396
1389507_at Nedd4l 2.97 0.0048 0.51 1.42 0.0043 1.00 0.0306
1375138_at Timp3 2.92 0.0054 0.56 1.22 0.0134 1.00 0.0319
1370530_a_at Pld1 -2.81 0.0071 0.14 -1.34 0.0062 1.00 0.0493
1385778_at Siat7E 2.79 0.0075 1.15 1.38 0.0055 1.00 0.0276
1395986_at Slit2 -2.78 0.0077 0.14 -1.27 0.0094 1.00 0.0419
1369973_at Xdh 2.76 0.0080 1.15 1.18 0.0167 1.00 0.0472
1368438_at Pde10a 2.70 0.0094 1.16 1.11 0.0255 1.00 0.0496
1387260_at Klf4 -2.69 0.0096 0.14 -1.49 0.0026 1.00 0.0429
1372356_at Usp54 2.69 0.0097 1.16 1.12 0.0240 1.00 0.0442
1371442_at Hyou1 2.68 0.0099 1.16 1.03 0.0384 1.00 0.0467
1375296_at LOC684097 2.66 0.0105 1.16 1.40 0.0047 1.00 0.0427
1398899_at Polr2c 2.64 0.0110 1.16 1.67 0.0009 1.00 0.0195
1377518_at Camk1g** 2.59 0.0123 1.16 1.29 0.0090 1.00 0.0315
1372090_at Max 2.53 0.0143 1.16 1.31 0.0080 1.00 0.0306
1381557_at Gna14 2.35 0.0216 1.16 1.29 0.0087 1.00 0.0442
1398373_at B3galt3 2.29 0.0248 1.16 1.29 0.0091 1.00 0.0396
1372037_at Pdlm7 2.18 0.0319 1.16 1.28 0.0098 1.00 0.0351
1382112_at LOC682926 -2.16 0.0333 1.15 -1.26 0.0096 1.00 0.0344
1375752_at Bves -1.96 0.0519 1.15 -1.41 0.0042 1.00 0.0376
1370869_at Bcat1 1.92 0.0561 1.16 1.28 0.0096 1.00 0.0345
1367706_at Vdac1 1.74 0.0820 1.16 1.29 0.0090 1.00 0.0295
** = genes examined by qRT-PCR. Positive SAM di or PIR Mi scores denote upregulated probe sets. Negative SAM di or PIR Mi scores denote 
downregulated probe sets. A full list of probe sets altered by deltamethrin exposure, including predicted protein coding sequences and expressed 
sequence tags is given in Additional file 3.Page 5 of 23
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2-ΔΔCT as the dependent variable followed by Dunnett's
mean contrast test. Transcripts with a significant com-
pound by EDL interaction were further analyzed using a
one-way ANOVA with dose as the independent variable
followed by Dunnett's mean contrast test. Statistical anal-
ysis of time course data was performed using a two-way
ANOVA with time and treatment as independent variables
and 2-ΔΔCT as the dependent variable. Transcripts with a
significant time*treatment interaction (p < 0.05) were
additionally analyzed with a one-way ANOVA at each
time point with treatment as the independent variable (p
< 0.05).
Significance Analysis of Function and Expression (SAFE)
The SAFE method was used to identify pathways/func-
tional categories whose genes are coordinately regulated
in a dose-dependent manner [36]. SAFE is similar to other
pathway enrichment procedures (e.g. DAVID) [45], but
accounts for correlation in gene expression within path-
ways using array permutation to rigorously control error
rates. SAFE and accompanying array annotation were
loaded from Bioconductor v.1.8 [46]. SAFE tests for
enrichment of significant dose-response relationships for
genes within each pathway. Following calculation of lin-
ear regression dose-response p-values for each gene, only
genes with a nominal p-value < 0.05 were used to form the
gene list to which the enrichment analysis was performed.
SAFE [47] enables the user to define a pathway enrich-
ment statistic and a Pearson test of binomial proportions
was then implemented [48]. The Pearson statistics is sim-
ilar to Fisher's exact test commonly employed in pathway
enrichment testing (GSEA) [49], but does not consider the
number of significant genes to have been fixed a priori
[50]. 10,000 permutations of dose levels were used by
SAFE to assess the significance of the entire procedure,
using the Yekutieli and Benjamini (1999) procedure to
control the FDR while accounting for the multiple path-
ways/categories [51]. All categories with an estimated FDR
< 0.1 are reported in Table 5.
Combining pathway evidence for the two pyrethroids
One aim of using the SAFE statistical methods in this
study was to identify gene categories showing enrichment
for dose-responsiveness for both permethrin and deltam-
ethrin. The Fisher combined p-value method allows
accrual of evidence across multiple hypotheses, and thus
is ideal for testing combined evidence for enrichment of
each pathway for both chemicals [52]. Under the null
hypothesis that neither chemical shows enrichment for
the pathway, each of the two p-values is uniform [0,1],
and the Fisher statistic
S = -2(ln(pdelta)+ln(pnorm))
is distributed as . The Fisher approach has favorable
optimality properties [53] and results in a new (com-
bined) p-value for each pathway. For the multiple path-
ways tested, the Benjamini-Hochberg (1995) method was
χ22
Table 3: Probe sets identified as dose-responsive for permethrin.
Linear Regression (SAM) Isotonic Regression (PIR) ANOVA
Affymetrix Probe Set I.D. Gene Symbol di p-value q-value Mi p-value q-value p-value
1369303_at Crh 4.26 0.0001 0.00 1.92 0.0003 1.00 0.0113
1368677_at Bdnf** 3.85 0.0003 0.00 1.52 0.0025 1.00 0.0170
1370412_at Slc40a1 -3.50 0.0006 0.18 -1.70 0.0016 1.00 0.0050
1370415_at Rassf5** 3.37 0.0008 0.12 1.85 0.0004 1.00 0.0170
1375043_at c-fos** 3.23 0.0012 0.18 1.41 0.0045 1.00 0.0170
1395991_at Rimbp2 3.11 0.0016 0.28 1.39 0.0050 1.00 0.0400
1388583_at Cxcl12 2.92 0.0027 0.42 1.36 0.0057 1.00 0.0477
1368321_at Egr1** 2.87 0.0030 0.50 1.21 0.0132 1.00 0.0230
1369067_at Nr4a3 2.77 0.0040 0.55 1.15 0.0187 1.00 0.0270
1387025_at Dync1i1 2.76 0.0041 0.55 1.29 0.0085 1.00 0.0208
1381557_at Gna14 2.67 0.0052 0.61 1.87 0.0004 1.00 0.0176
1387024_at Dusp6 2.59 0.0064 0.75 1.01 0.0398 1.00 0.0230
1388911_at Prim2 2.50 0.0082 0.79 1.45 0.0036 1.00 0.0408
1385778_at Siat7E 2.36 0.0116 0.79 1.43 0.0041 1.00 0.0305
1395272_at LOC682937 -1.88 0.0394 0.69 -1.33 0.0084 1.00 0.0305
1367652_at Igfbp3 1.38 0.1190 0.79 1.35 0.0063 1.00 0.0358
1389090_at Wrnip1 1.32 0.1319 0.79 1.30 0.0079 1.00 0.0170
1376602_a_at Fbxo22 0.89 0.2974 1.32 1.27 0.0096 1.00 0.0186
1391301_at LOC682355 0.51 0.5404 1.32 1.35 0.0062 1.00 0.0305
** = genes examined by qRT-PCR. Positive SAM di or PIR Mi scores denote upregulated probe sets. Negative SAM di or PIR Mi scores denote 
downregulated probe sets. A full list of probe sets altered by deltamethrin exposure, including predicted protein coding sequences and expressed 
sequence tags is given in Additional file 4.Page 6 of 23
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[54].
Fisher's statistic can be asymmetrically sensitive to very
small p-values for a single chemical, even if the results for
the other chemical are not significant. Thus, among path-
ways with a significant Fisher statistic, the focus was
placed on those which showed SAFE p-values < 0.05 for
both chemicals.
Cell culture and treatment
Cortical cultures containing neurons and glia were pre-
pared from neocortices of newborn rat pups according to
the protocol used by Chandler et al. (1993) with modifi-
cations [55]. Neocortices were harvested under sterile con-
ditions in a buffer solution containing 137 mM NaCl, 5
mM KCl, 170 μM Na2HPO4, 205 μM KH2PO4, 5 mM glu-
cose, 59 mM sucrose, 100 U/ml penicillin and 0.1 mg/ml
streptomycin, pH 7.4. The cortices were minced with scis-
sors and digested using 0.25% trypsin for 5 minutes, then
with addition of 0.016% DNase for a further 5 minutes at
Table 4: qRT-PCR confirmation of transcripts identified as dose-responsive.
Deltamethrin Permethrin
Camk1ga qRT-PCR 1391229_at 1377518_at qRT-PCR 1391229_at 1377518_at
Control 1.03 ± 0.10 1.00 ± 0.04 1.00 ± 0.05 1.04 ± 0.13 1.00 ± 0.04 1.00 ± 0.05
< NOAEL 1.23 ± 0.18 1.10 ± 0.03 1.07 ± 0.08 1.05 ± 0.14 1.16 ± 0.10 1.20 ± 0.13
NOAEL 1.40 ± 0.18 1.26 ± 0.07 1.31 ± 0.06 1.97 ± 0.28* 1.09 ± 0.05 1.09 ± 0.09
ED30 1.57 ± 0.14* 1.31 ± 0.06 1.39 ± 0.06 1.76 ± 0.32*
ED50 1.72 ± 0.30* 1.25 ± 0.09 1.45 ± 0.17
Ddc a qRT-PCR 1368064_a_at qRT-PCR 1368064_a_at
Control 1.01 ± 0.06 1.00 ± 0.03 1.04 ± 0.12 1.00 ± 0.03
< NOAEL 0.79 ± 0.06 0.96 ± 0.04 0.97 ± 0.10 1.04 ± 0.04
NOAEL 0.89 ± 0.07 0.90 ± 0.05 0.91 ± 0.10 1.01 ± 0.04
ED30 0.70 ± 0.05* 0.80 ± 0.03 0.81 ± 0.11*
ED50 0.71 ± 0.09* 1.00 ± 0.05
Gpd1b qRT-PCR 1371363_at 1369560_at qRT-PCR 1371363_at 1369560_at
Control 1.06 ± 0.13 1.00 ± 0.11 1.00 ± 0.08 1.04 ± 0.14 1.00 ± 0.11 1.00 ± 0.08
< NOAEL 1.16 ± 0.13 0.88 ± 0.07 0.88 ± 0.05 0.94 ± 0.07 1.03 ± 0.10 0.98 ± 0.09
NOAEL 1.04 ± 0.12 1.42 ± 0.17 1.25 ± 0.13 0.97 ± 0.06 1.03 ± 0.09 0.95 ± 0.10
ED30 2.04 ± 0.28* 1.94 ± 0.19 1.55 ± 0.14 1.24 ± 0.15
ED50 1.23 ± 0.13 1.19 ± 0.18 1.12 ± 0.16
Fkbp51 b qRT-PCR 1388901_at 1380611_at qRT-PCR 1388901_at 1380611_at
Control 1.01 ± 0.06 1.00 ± 0.05 1.00 ± 0.04 1.02 ± 0.09 1.00 ± 0.05 1.00 ± 0.04
< NOAEL 0.92 ± 0.06 1.00 ± 0.03 1.04 ± 0.07 1.03 ± 0.09 0.92 ± 0.05 0.96 ± 0.07
NOAEL 1.02 ± 0.07 1.17 ± 0.05 1.16 ± 0.08 1.00 ± 0.06 1.06 ± 0.03 0.99 ± 0.06
ED30 1.52 ± 0.14* 1.41 ± 0.09 1.35 ± 0.10 0.95 ± 0.07
ED50 1.03 ± 0.12 1.07 ± 0.05 1.07 ± 0.09
c-fos c qRT-PCR 1375043_at qRT-PCR 1375043_at
Control 1.19 ± 0.27 1.00 ± 0.16 1.09 ± 0.21 1.00 ± 0.16
< NOAEL 0.63 ± 0.14 1.01 ± 0.31 1.49 ± 0.25 0.54 ± 0.07
NOAEL 1.09 ± 0.43 0.72 ± 0.12 1.30 ± 0.22 0.57 ± 0.08
ED30 0.54 ± 0.08* 0.69 ± 0.06 0.91 ± 0.11
ED50 1.25 ± 0.27 1.56 ± 0.34
Egr1 c qRT-PCR 1368321_at qRT-PCR 1368321_at
Control 1.04 ± 0.12 1.00 ± 0.08 1.01 ± 0.07 1.00 ± 0.16
< NOAEL 0.81 ± 0.05 0.93 ± 0.09 1.10 ± 0.10 0.77 ± 0.02
NOAEL 0.90 ± 0.16 0.95 ± 0.08 1.10 ± 0.11 0.89 ± 0.09
ED30 0.87 ± 0.07 0.98 ± 0.06 1.09 ± 0.08
ED50 1.12 ± 0.10 1.19 ± 0.08
Values in normal type-set are 2-ΔΔCT (± SE) from qRT-PCR Cohort 3. For comparison, values in italics are fold-change from control (± SE) for 
microarray probe sets (Cohorts 1 & 2). Groups for statistical analysis are given in Table 1. Equipotent dose groups are based on Wolansky et al 
(2006). Main effects in two-way ANOVA: a = EDL (p < 0.05), b = COMPOUND*EDL (p < 0.05) and DOSE (p < 0.05) for deltamethrin only in one-
way ANOVA, c = COMPOUND (p < 0.05). * = Significance difference from control in a Dunnett's mean contrast test (p < 0.05).Page 7 of 23
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(400 × g, 1600 rpm) for 5 minutes at room temperature,
the supernatant was aspirated and the tissue pellet was re-
suspended in Gibco® DMEM/GlutaMAX-1 (Invitrogen
Corp, Carlsbad, CA) containing 10 mM HEPES, 100 U/ml
penicillin, 0.1 mg/ml streptomycin and 10% horse serum,
pH = 7.4. The tissue was dissociated by trituration and fil-
tered through a 100-μm Nitex screen. Cells were plated at
a density of 50,000 cells/well in 96-well polystyrene plates
(Corning, Inc., Corning, NY) that had been pre-coated
with poly-L-lysine. Cells were incubated at 37°C in a
humidified atmosphere of 5% CO2 and 95% air.
Multi-compartment pharmacokinetic models for the dis-
position of deltamethrin and permethrin were used to
predict tissue concentrations of deltamethrin and per-
methrin in the brain at 6 h following the acute adminis-
tered doses used in this study [56,57]. Predictions are
listed in Table 6. These estimated brain concentrations
were then used to select nominal media concentrations of
pyrethroids for use in the functional neurite morphogen-
esis cell model.
For in vitro exposure of cells, pyrethroids were prepared in
DMSO using semi-logarithmic serial dilutions of concen-
trated stock solutions to yield final chemical concentra-
tion ranges of 0.001 – 0.03 μM and 0.01 – 3 μM for
deltamethrin and permethrin, respectively. The final
DMSO concentration in the cortical media was 0.1%.
Chemicals were added to the cells 2 hours after plating to
ensure the cells adhered to the poly-L-lysine and incu-
bated for a 96-hour exposure period.
Evaluation of neurite outgrowth and cell viability
Immunocytochemical staining with a Neurite Outgrowth
Hitkit (Thermo-Fisher Scientific, Waltham, MA) and sub-
sequent analysis using a Cellomics ArrayScan VTI high
content imaging platform was used to evaluate cortical
cell neurite outgrowth and branching as described in
Radio et al. (2008) for differentiated PC-12 cells [58]. The
Cellomics ArrayScan VTI Neuronal Profiling Bioapplica-
Table 5: Significant Analysis of Function and Expression (SAFE) results.
Commonly enriched gene categories for both permethrin and deltamethrina
Category I.D. and name sizeb DLT p-value PERM p-value
GO Biological Process
GO:0048754, 'branching morophogenesis of a tube' 66 0.0171 2.00E-04
GO:0001763, 'morphogenesis of a branching structure' 67 0.0172 2.00E-04
GO:0007162, 'negative regulation of cell adhesion' 27 0.0175 0.0025
GO:0015718, 'monocarboxylic acid transport' 30 0.0051 0.0125
GO:0007498, 'mesoderm development' 57 0.0105 0.0067
GO Cellular Component
GO:0005954, 'Ca+2 and calmodulin-dependent protein kinase complex' 25 0.0053 0.0146
GO Molecular Function
GO:0046915, 'transition metal ion transporter activity' 44 0.0026 0.0348
Enriched gene categories identified by SAFE.
Category I.D. and name sizeb p-valuec
Deltamethrin
KEGG Pathway
KEGG:00564, 'Glycerophospholipid metabolism' 73 0.0404
KEGG:00400, 'Phenylalanine, tyrosine and tryptophan biosynthesis 12 0.0928
Permethrin
GO Biological Process
GO:0048754, 'branching morphogenesis of a tube' 66 0.0349
GO:0001763, 'morphogenesis of a branching structure' 67 0.0349
GO:0001569, 'patterning of blood vessels' 31 0.0406
GO:0009880, 'embryonic pattern specification' 49 0.0554
GO:0045655, 'regulation of monocyte differentiation' 32 0.0932
a GO catergories or KEGG pathways with p < 0.05 for both test compounds using Fisher's combined p-value method to test for joint enrichment in 
the SAFE procedure. b number of Affymetrix probe sets included in GO category or KEGG pathway groupings. c GO categories or KEGG pathways 
with an adjusted p < 0.1 for SAFE method. 700 GO-BP (biological processes), 142 GO-CC (cellular component), 307 GO-MF (molecular function) 
and 126 KEGG pathways were examined.Page 8 of 23
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number of fields for the analysis of at least 200 cells per
well. Data represent the mean ± standard error across 3
replicate experiments. Cellular viability was determined
in cortical cell cultures grown as described above in
opaque 96-well plates using the CellTiter-Glo Viability
Assay (Promega Corp., Madison, WI) as described in
Radio et al. (2008) [58]. Luminescence was measured
thirty minutes after adding the reagent using a FLUOstar
Optima plate reader (BMG LABTECH, Durham, NC).
Results
Microarray dose-response analyses
Both the PIR (isotonic) and SAM (linear) penalized
regression methods identified dose-dependent increases
and decreases in mRNA expression in the frontal cortex 6
h after an acute, oral exposure to both deltamethrin and
permethrin. A comparison of the PIR and SAM regression
models demonstrate that the two methods yield similar
results in terms of identifying dose-responsive probe sets
for both deltamethrin and permethrin (Figure 1A &1B).
SAM analyses identified a small number of probe sets with
dose-dependent increases in expression following either
deltamethrin (n = 7) or permethrin (n = 10) exposure
using the permutation-based FDR values as the signifi-
cance criteria (q < 0.10, see Figure 1A &1B). The PIR anal-
yses did not identify any probe sets for either pyrethroid
with dose-dependent changes in expression at q < 0.10. A
less statistically conservative method of identifying dose-
related changes in probe set expression identified a larger
number of significantly altered probe sets than that
observed using the FDR criteria. Using a screening thresh-
old of p < 0.01 the SAM analysis identified 70 and 61
probe sets with dose-dependent changes in expression for
deltamethrin and permethrin, respectively, while the PIR
analysis identified 93 and 85, respectively (Figure 1A–B).
The overlap between probe sets identified as dose-respon-
sive using the empirical p-value thresholds is considerable
but incomplete. Overall, these parallel methods yield
comparable results in that a rank-ordered list of dose-
dependent changes in expression constructed using either
the PIR or SAM test-statistics identifies the same groups of
probe sets as being the most significantly changed within
both the deltamethrin and permethrin test cohorts
To minimize the inclusion of false positives in qRT-PCR
prioritization lists, all the probe sets for each compound
that had empirical p-values < 0.01 in either the SAM or PIR
regression methods were additionally analyzed with a
one-way ANOVA with dose as the independent factor, fol-
lowed by a Benjamini-Hochberg multiple testing correc-
tion (significance threshold, p < 0.05). For deltamethrin
and permethrin, 95 of 109 (87.1%) and 53 of 89 (59.5%)
probe sets passed the ANOVA significance threshold. The
full list of probe sets considered significantly dose-respon-
sive for deltamethrin (n = 95) and permethrin (n = 53) are
listed in Additional files 3 and 4. Probe sets included in
Additional files 3 and 4 that correspond to known pro-
tein-coding RefSeq database entries were considered can-
didates for qRT-PCR confirmation in dose-response
Cohorts 3 and 4 and are listed in Tables 2 and 3.
The dose-dependent changes in mRNA expression identi-
fied with the above analyses are relatively small in magni-
tude, < 2-fold change from control, and have varying
patterns of expression across dose (Figure 2). Post-hoc
analysis (Dunnett's mean contrast test) of these dose-
response functions indicate that significant alterations in
mRNA expression occur at doses below those needed to
produce acute behavioral effects (Figure 2, insets). A
majority of the probe sets identified as dose-responsive
had mean expression values in the 3 mg/kg deltamethrin
and 100 mg/kg permethrin dose groups different from
those in the vehicle treated control group (78.9% and
77.3%, respectively). Of those probe sets, 25.3% and
19.5% also had mean expression values in the 1 mg/kg
deltamethrin and 10 mg/kg permethrin dose groups dif-
ferent from controls. These latter doses are below those
needed to produce acute neurotoxic effects on behavior.
In addition, these data demonstrate that the PIR analyses
detected a greater number of probe sets with mean expres-
sion values in the behavioral "NOAEL" dose groups (see
Table 1) as being different from control as compared to
the SAM analyses (compare Figure 2B &2E, insets to Fig-
Table 6: Pharmacokinetic estimates of pyrethroid brain concentrations.
Administered Dose (mg/kg) Time (h) Brain Concentration (μM)
Deltamethrina 0.3 6 0.005
1 6 0.0169
3 6 0.050
Permethrinb 1 6 0.060
10 6 0.582
100 6 5.940
a Estimates based on Mirfazaelian et al. (2006).
b Estimates based on Tornero-Velez et al. (2007).Page 9 of 23
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Comparison of PIR and SAM regression methodsFigure 1
Comparison of PIR and SAM regression methods. Panels A & B plot the penalized isotonic regression (PIR) test statistic 
(Mi, x-axis) against the penalized linear regression (SAM) test statistic (di, y-axis) for deltamethrin and permethrin, respectively. 
All 31,042 probe sets present on the Affymetrix Rat 230 2.0 GeneChip® are shown. Data points in green have an empirical p-
value < 0.01 for both the PIR and SAM methods. Data points in blue have an empirical p-value < 0.01 for the PIR regression 
only. Data points in orange have an empirical p-value < 0.01 for the SAM regression only. In the deltamethrin and permethrin 
analyses, 49.5% and 53.7% of all probe sets identified by either the PIR or SAM method had p < 0.01 for both methods. Data 
points circled in red have a q-value < 0.10 in permutation-based FDR calculations employed in the SAM algorithm. Note that 
the rank order of statistical significance was similar between the two methods in that probe sets commonly identified using the 
PIR or SAM method tend to appear in the upper-right and lower left hand corners of the scatterplots (green points).
BMC Genomics 2008, 9:546 http://www.biomedcentral.com/1471-2164/9/546ure 2C &2F, insets).
Comparison of transcriptional effects across compounds
A comparison of the probe sets identified as dose-respon-
sive in the PIR and SAM regression analyses demonstrates
that the transcriptional response elicited by the two pyre-
throids has some common characteristics. The panels in
Figures 3 plot the -log10 of the empirical p-values associ-
ated with the PIR regression (3A) or SAM regression (3B)
for each probe set identified as dose-responsive for either
deltamethrin or permethrin. Data from the PIR regression
analyses demonstrate that expression of 27.2% of all
probe sets identified as dose-responsive for either pyre-
throid are significantly altered by both compounds at an
empirical p-value threshold of p < 0.05 (Figure 3A). Like-
wise, SAM analyses demonstrated that 27.8% of all dose-
responsive transcripts are altered by both pyrethroids (Fig-
ure 3B). Differences in the global transcriptional response
profiles between pyrethroids are also apparent.
Quantitative real-time RT-PCR
Table 4 summarizes the results of the qRT-PCR assays and
compares them to the fold-change expression values
derived from the microarray study. Of the nine transcripts
examined by qRT-PCR in Cohort 3, Ca+2/calmodulin
dependent protein kinase 1γ (Camk1g) and dopa decar-
boxylase (Ddc) were commonly affected by both com-
pounds indicating that for these genes there was no
differences in the changes in expression elicited by equi-
potent doses of either pyrethroid. Camk1g qRT-PCR
expression values closely resembled those observed in the
microarray study. In contrast to Camk1g, the microarray
Dose-response functions identified by PIR and SAM regression methodsFigure 2
Dose-response functions identified by PIR and SAM regression methods. Panels A-F plot dose-response functions 
for probe sets identified by PIR (B & E), SAM (C & F) or both regression methods (A & D) for deltamethrin (A-C) and per-
methrin (D-F). Only probe sets that had a Benjamini-Hochberg adjusted p-value < 0.05 for a main effect of dose in a one-way 
ANOVA are shown. For each probe set expression summaries for each treatment group were normalized to vehicle control 
and plotted as fold-change from control. The color scheme corresponds to that used in Figure 1, with green curves being 
detected by both PIR and SAM regression methods (A, D), blue curves being detected exclusively with the PIR method (B, E) 
and orange curves being detected exclusively with the SAM method (C, F). Insets on each panel are the summated results of a 
Dunnett's many-to-one mean contrast test performed within each probe set comparing the means of the lowest (C-L), middle 
(C-M) and highest (C-H) doses to the mean of vehicle treated control. y-axis is number of probe sets identified under each 
comparison at a significance level of p < 0.05. Note the green portion of the stacked bars in the insets are the same values in 
inset panels A-C and D-E, respectively.Page 11 of 23
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in Ddc expression for deltamethrin only, even though a
clear dose-dependent decrease in Ddc mRNA expression
was observed in both the deltamethrin and permethrin
qRT-PCR cohorts.
A significant interaction between compound and EDL was
observed for glycerol-3-phosphate dehydrogenase 1
(Gpd1) and FK506-binding protein 5 (Fkbp51), indicating
that equipotent doses of the two pyrethroids did not elicit
similar changes in expression at 6 h post-exposure. A main
effect of dose was observed for Gpd1 and Fkbp51 mRNA
only for deltamethrin (Table 4). The qRT-PCR expression
values for Gpd1 and Fkbp51 closely match those observed
in the microarray study.
The immediate early genes (IEG), FBJ murine osteosar-
coma viral oncogene homolog (c-fos) and early growth
response 1 (Egr1) were differentially affected by the two
pyrethroids at 6 h post-exposure, however, no significant
main effect of dose (EDL) was observed for either com-
pound. For deltamethrin, the direction of fold-change for
c-fos and Egr1 is down in most dose groups measured by
qRT-PCR. In contrast, for permethrin no change in the
expression of c-fos and Egr1 mRNA was observed across
dose groups in the qRT-PCR cohort. While c-fos and Egr1
expression at 3 mg/kg deltamethrin and 100 mg/kg per-
methrin reflect the direction of fold-change observed in
the microarray study, very little similarity is apparent
between qRT-PCR and microarray expression values for
these genes at the lower dose levels (Table 4).
There were no effects of pyrethroid exposure on mRNA
expression for heat shock 27 kDa protein (Hsp27), brain
derived neurotrophic factor (BDNF) or Ras association
(RalGAS/AF-6) domain family 6 (Rassf5) (data not
shown). In the case of BDNF, qRT-PCR expression values
closely approximate the expression values observed in a
second probe set not identified as dose-responsive in the
microarray analyses (data not shown).
Characterization of the time course of mRNA expression
for Camk1g, Gpd1, c-fos and Egr1 demonstrates that altered
expression of these transcripts also occurs at times earlier
than 6 h following acute, oral pyrethroid exposure (Figure
4, Additional file 5). Treatment-related increases in
Camk1g and Gpd1 mRNA expression were observed for
both deltamethrin and permethrin. For deltamethrin,
Comparison of probe sets identified by PIR or SAM between pyrethroidsFigure 3
Comparison of probe sets identified by PIR or SAM between pyrethroids. Panels A and B plot the -log10 (empirical p-
value) for deltamethrin (x-axis) against the -log10 (empirical p-value) for permethrin (y-axis) for probe sets identified during PIR 
or SAM regression analyses, respectively. All probe sets that had a Benjamini-Hochberg adjusted p-value < 0.05 in a one-way 
ANOVA for either permethrin or deltamethrin are included in the plot. Dashed boxes represent empirical p-value thresholds 
of p < 0.05. All points in the upper right of the figures, within the dashed boxes, meet the respective p-value criteria for both 
pyrethroids. 27.2% and 27.8% of all probe sets identified during PIR or SAM analysis, respectively, had empirical p-values of p < 
0.05 for both compounds.
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expression at 3 h followed by persistent elevations at 6 h
(Figure 4). For permethrin, both Camk1g and Gpd1 had
maximal induction at 6 h preceded by slight elevations at
3 h. Permethrin-mediated Gpd1 induction was statistically
significant while Camk1g induction reflected the trends
observed in the dose-response cohorts but did not reach
statistical significance. Ddc mRNA expression was
decreased following both deltamethrin and permethrin
exposure. For deltamethrin decreased expression began at
6 h and persisted through 9 h while for permethrin,
expression decreased at 6 h only. The changes in Ddc
mRNA expression over time were consistent with those
observed in the qRT-PCR cohort
Both deltamethrin and permethrin increase the expres-
sion of the IEGs c-fos and Egr1, albeit with different tem-
poral characteristics. Expression of c-fos and Egr1 increases
at 3 h for deltamethrin and returns to control levels at 6 h.
For permethrin, expression of c-fos and Egr1 increases at 3
h, remains persistently elevated at 6 h and returns to con-
trol levels by 9 h. The large increases in c-fos and Egr1 for
permethrin and not deltamethrin are consistent with the
microarray data as these two genes were identified as
dose-responsive at 6 h for the former and not the latter
compound. However, the data in Figure 4 demonstrate
that the two pyrethroids, in fact, elicit qualitatively similar
responses in the expression of c-fos and Egr1. The expres-
sion of another IEG, BDNF, is apparently not affected by
pyrethroids under the dosing paradigm used in this study.
Significant Analysis of Function and Expression (SAFE)
Seven GO categories were identified as commonly
enriched for both pyrethroids using SAFE analysis and
Fisher's χ2 method (Table 5). The composition of the
commonly enriched categories for both chemicals
included genes involved in neuronal morphogenesis,
intracellular Ca+2 signaling and small molecule transport.
In addition, five GO-BP categories and two canonical
KEGG pathways were identified as enriched in the indi-
vidual SAFE analyses of permethrin and deltamethrin,
respectively (Table 5). For permethrin, the SAFE findings
include enriched gene categories related to neuronal mor-
phogenesis and developmental patterning. For deltameth-
rin the SAFE findings include two KEGG metabolic
pathways, one of which involves synthesis of the precur-
sor molecules for monoamine neurotransmitters.
SAFE plots of the GO categories 'morphogenesis of a
branching structure' and 'Ca+2/calmodulin dependent
protein kinase complex' demonstrate the significant cate-
gory enrichment for both permethrin and deltamethrin
(Figure 5). This is evidenced by the divergence of the stair
step line from the unity line near the far left of Figure 5,
panels A-D. A SAFE plot of a GO category not significantly
enriched for either compound is given in Figure 5, panels
E-F for comparison purposes. The most significant dose-
responsive transcripts for each of the enriched GO catego-
ries are illustrated in the heatmaps to the right of Figure 5,
panels A-D. These heatmaps demonstrate that appreciable
dose-dependent increases in the expression of probe sets
contained within the enriched GO categories occurs fol-
lowing pyrethroid exposure.
Pyrethroid effects on neurite length and branching in 
primary mixed cortical cell cultures
Both deltamethrin and permethrin produce an increase in
the number of neurite branch points following a 96 h
exposure (Figure 6A &6D). The range of predicted tissue
concentrations (in μM) from the pharmacokinetic predic-
tions listed in Table 6 are marked near the x-axes and cor-
respond well to areas along the in vitro dose-response
curve where changes in branching were observed. An aver-
age increase of ~25% above control in the number of neu-
rite branch points was observed at nominal media
concentrations ranging from 0.01 – 0.03 μM deltamethrin
and 0.01 – 3 μM permethrin. No significant increase in
total neurite length was observed for either compound
save at the 0.01 μM exposure level for permethrin (Figure
6B &6E). Changes in cell viability were not apparent in the
concentration ranges tested (Figure 6C &6F).
Discussion
A principle finding of the present study was that dose-
dependent alterations in gene transcription occur in the
cortex at doses of deltamethrin and permethrin below
those required to elicit acute neurotoxic effects in the
whole animal. Both similarities and differences in the
overall transcriptional response were observed when com-
paring the two pyrethroids. Quantitative real-time RT-
PCR analysis in additional cohorts of animals provided
independent biological and technical replicates of the
findings from the microarray data set. In addition, tran-
scripts for which the time course of gene expression was
characterized demonstrated qualitative similarities in the
response for both pyrethroids. SAFE analysis of the micro-
array data identified several GO categories jointly
enriched by both deltamethrin and permethrin including
some related to branching morphogenesis. Subsequently,
a significant increase in the number of neurite branch
points was observed in a primary cortical cell culture
model.
Microarray dose-response analyses
Dose-dependent alterations in transcript expression were
observed in frontal cortex 6 h following acute exposure to
pyrethroids. Prior to experimentation, the shape of the
dose-response curve for any potential alterations in gene
transcription was unknown. Visual inspection of the data
demonstrated a definite heterogeneity in the types ofPage 13 of 23
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qRT-PCR time course resultsFigure 4
qRT-PCR time course results. Transcript expression over time following a single acute dose of 3 mg/kg deltamethrin (top) 
or 100 mg/kg permethrin (bottom). Gene symbols are listed on the y-axis. Data were analyzed using two-way ANOVA fol-
lowed by one-way ANOVA within time points were interaction was observed. (**) denotes no interaction of time and treat-
ment and a main effect of treatment (p < 0.05). (‡) denotes no interaction of time and treatment and a main effect of both time 
and treatment (p < 0.05). (*) denotes a significant effect of treatment for that time point (p < 0.05). (†) denotes a significant 
main effect of dose from qRT-PCR dose-response analysis (Table 4). Values for time-matched vehicle controls are not shown. 
A summary of the statistical analyses performed on these data is provided in Additional file 5.
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exposures (see Figure 2). The biological factors mediating
this heterogeneity are unclear but may involve activation
of different intracellular signaling pathways at different
points along the dose range [59-62]. To generate lists of
candidate genes for qRT-PCR follow-up that captures this
heterogeneity, the GeneChip® expression data was ana-
lyzed using two independent but similarly structured
regression methods: SAM and a novel PIR. Both methods
identified qualitatively similar dose-related alterations in
gene expression within each compound (Figure 1A &1B).
The SAM regression model detected a number of dose-
responsive transcripts with expression levels different
from control only at the highest pyrethroid dose (Figure
2). However, PIR identified other dose-related changes
with small, but significant, increases or decreases in
expression that were similar in magnitude at both the
"NOAEL" and "high" pyrethroid doses (Figure 2B &2E)
and not detected by SAM. These dose-responsive tran-
scripts may in fact be biologically relevant responses to
acute pyrethroid intoxication which would have been
excluded using the standard SAM analysis. Therefore,
while both SAM and PIR identified the same sub-set of
transcripts within compound, the PIR method detected a
larger component of the global transcriptional response
of the cortex composed of expression changes that do not
fit a linear model.
The regression analysis frameworks detailed in this work
were used exclusively as an identification and prioritiza-
tion method for selection of genes for subsequent qRT-
PCR analyses. Conclusions concerning the biological sig-
nificance of individual transcriptional changes were
reserved for those transcripts successfully replicated by
qRT-PCR in independent cohorts of test subjects. For the
goals of this study, the risk of excluding true positives in
the microarray data analysis outweighed the caveat of
including false positives from the final list of prioritized
targets. Thus, the modified protocol of regression screen-
ing and subsequent ANOVA based analyses was adopted.
Comparison across compounds
The present data demonstrate both similarities and differ-
ences in the global transcriptional response in rat cortex to
acute, low-dose deltamethrin and permethrin exposure.
Similarities in the global transcriptional response across
compounds suggest that these two pyrethroids may affect
common biological pathways (Figure 3). The differences
observed between compounds in the global transcrip-
tional response (i.e. microarray dataset) are likely due to a
combination of two factors: 1) authentic heterogeneity in
the pharmacodynamic activities of deltamethrin and per-
methrin on gene transcription and 2) a slight offset in the
time course of qualitatively similar responses across com-
pounds. In addition, time course data implies that addi-
tional alterations in gene expression not detected in the 6
h dose-response study may occur at time points other
than the one sampled. The qRT-PCR data shown here sup-
port this conclusion (Figure 4).
The results of the SAFE functional category level analysis
support the conclusion that the biological activities of the
two pyrethroids overlap. Several categories were found to
be commonly upregulated between the two compounds.
Similarities are not surprising, given that both pyrethroids
act on mammalian VSSCs [12,32]. Whether the individual
gene changes or impacted functional categories are
directly linked to this site of action, remains yet to be
determined. Importantly, these data provide guidance on
some novel cellular functions affected by pyrethroids.
Biological significance of experimental findings
Interestingly, probe sets corresponding to the primary
molecular targets for pyrethroids were not altered for
either pyrethroid tested in the microarray study. Specifi-
cally, there were no treatment related changes in any of
the VSSC or VSCC isoforms/subunits or any subunits that
comprise neurotransmitter receptors complexes [63-66].
This finding is supported by in vitro data [27] that charac-
terized the global transcriptional response of cortical neu-
rons exposed to a variety of pharmacological agents that
Composition and expression patterns of significantly enriched GO categories from SAFE analysisFigure 5 (see previous page)
Composition and expression patterns of significantly enriched GO categories from SAFE analysis. Panels A-D 
are SAFE plots for two commonly enriched categories for both deltamethrin (A & C) and permethrin (B & D). Panels E & F are 
SAFE plots for a category not enriched for either deltamethrin (E) or permethrin (F). The x-axis of each plot denotes the posi-
tion of all probe sets in a rank ordered list of significance (from left to right) according to the empirical p-value from a linear 
regression across dose. The y-axis is a cumulative percentage calculated by taking the rank position of a given probe set either 
within the entire data set (solid unity line) or the interrogated Gene Ontology sub-category (solid stair-step line) and dividing 
them by the total number of probe sets contained within the entire data set or interrogated category, respectively. The degree 
of deviation of the stair-step line from the unity line indicates enrichment. The probe sets (excluding ESTs) that are ranked 
highest in significance for each GO category for both compounds in panels A-B and C-D are denoted at the top of each panel 
and included in a heatmap to the side of the respective panels. In the heatmaps, each row of tiles is a probe set and each col-
umn of tiles represents the mean fold-change from control with increasing doses of each compound running from right to left. 
Colorbar for heatmaps is given in panel G.Page 16 of 23
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Pyrethroid effects on branching and neurite length in primary cortical cell culturesFigure 6
Pyrethroid effects on branching and neurite length in primary cortical cell cultures. Changes in the total number 
neurite of branch points (A & D), total neurite length (B & E) and cell viability (C & F) in primary cortical cell cultures exposed 
to deltamethrin (A-C) or permethrin (D-F). n = 3 replicate experiments. Values for each end point are normalized to 
untreated controls (± standard error). Untreated control values are shown in white. The bold lines underneath each curve 
represent the range of estimated brain concentrations expected to occur during the in vivo exposures used in the present study 
(Mirfazaelian et al. 2006 and Tornero-Velez et al. 2007). Significance was determined using a One-way ANOVA, * = p < 0.10, 
** = p < 0.05.
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or VSCC isoforms/sub-units or neurotransmitter receptors
were identified in this study in response to increases in
neuronal firing rates [27]. Since a primary action of pyre-
throids is to change firing rates [67], the present data do
not support transcriptional induction or repression of
VSSCs, VSCCs or neurotransmitter receptor subunits as a
neuronal response to acute pyrethroid exposure. These
data do not exclude transcription-independent changes in
the expression or functional state of these channels
known to occur following excitatory stimuli [68-71].
The immediate early transcription factors c-fos and Egr1
were upregulated by deltamethrin and permethrin. This is
consistent with IEG expression changes in the cortex fol-
lowing acute pyrethroid exposure [29,72]. Increased Egr1
and c-fos expression supports that deltamethrin and per-
methrin increased neuronal excitation in the present
study. Egr1 and c-fos are among the genes induced by
increased neuronal firing in cortical cells in culture [27],
as well as in vivo following stimuli that produce neuronal
excitation [73,74]. Induction of IEG mRNAs is a rapid
transcriptional response of neurons following increased
activity [75-78]. The time course for the expression of the
IEGs c-fos and Egr1 does not support de novo gene tran-
scription as being responsible for mediating the acute
behavioral effects of pyrethroids. The earliest time that
increased IEG expression is observed in the present study
is at 3 h: IEG expression is at control levels at 1 h. Onset
of behavioral effects following oral pyrethroid exposure
occurs prior to the onset of increased IEG expression (i.e.
30 min – 1 h) [79]. Therefore, the IEG induction described
here can not mediate the acute neurotoxic signs of pyre-
throid intoxication, but instead are markers of neuronal
excitation.
The present study found dose- and time-dependent
increases in the expression of Camk1g mRNA. Data from
in vitro models of developmental morphogenesis in neu-
rons indicates that increased expression of Camk1g (Table
4 and Figure 4) may alter the structure and function of
pyrethroid-sensitive neurons. Wayman et al. (2006) [80]
demonstrated that Camk1g plays a specific role in the
activity-dependent growth of hippocampal neurons
between 7-9DIV by activating a Ras/MEK/ERK/CREB/
Wnt2 signaling cascade in response to excitatory stimuli.
In addition, Takemoto-Kimura et al. (2007) [81] demon-
strated that Camk1g participates in a Rac signaling path-
way that mediates the morphogenesis of cortical neurons.
In both those studies, artificial knockdown or over-expres-
sion of Camk1g altered outgrowth of neuronal processes
in a development context [80,81]. The role of Camk1g in
maintenance and plasticity of neuronal processes in the
adult CNS is currently unknown. Furthermore, there is
evidence in the literature that Camk1g mRNA expression
is regulated by changes in neuronal firing patterns similar
to IEGs. Changes in neuronal firing rates correlates with
increases or decreases in the expression of Camk1g mRNA
[27,82-85]. These observations support that pyrethroid-
mediated changes in neuronal firing rates could mediate
changes in the expression of Camk1g, which may in turn
lead to changes in neuronal morphology (see below),
especially during development.
The transcriptional upregulation of glycerol-3-phosphate
dehydrogenase 1 (Gpd1) and FK506-binding protein
(Fkbp51) mRNA (Table 4, Figure 4) indicate: 1) that pyre-
throid exposure activates the hypothalamic-pituitary-
adrenal (HPA) axis and 2) that non-neuronal cell popula-
tions in the CNS are sensitive to pyrethroids. The proteins
encoded by Gpd1 and Fkbp51 are expressed in the brain
exclusively in oligodendrocytes [86] and T-cell lym-
phocytes [87]. Both the Gpd1 and Fkbp51 genes contain
glucocorticoid receptor binding motifs either in the
upstream promoter region (Gpd1) [88] or in an intronic
region (Fkbp51) [89] and increased expression of both is
dependent upon glucocorticoid hormone stimulation
[90,91]. Glucocorticoids are released in the circulation
from the adrenals in response to a variety of stressors and
increased circulating corticosterone levels were reported
in the rat following deltamethrin exposures; albeit at very
high, intravenous doses [92]. It is likely that increases in
Gpd1 and Fkbp51 expression may be components of a gen-
eralized, non-specific stress response brought about by
overstimulation of the HPA axis by pyrethroids. The
potential impact of increased Gpd1 and Fkbp51 expression
on the health and function of affected glia, to date, is
unclear.
Decreases in the expression of aromatic L-amino acid
decarboxylase (Ddc) suggest that pathways controlling
monoaminergic neurotransmitter synthesis may be
affected by pyrethroids. Ddc is the final enzyme in the syn-
thesis pathways of dopamine and serotonin [93]. Previ-
ous reports note a depletion of dopamine and serotonin
in a variety of brain regions following repeated exposure
to deltamethrin [94-96]. In the case of dopamine deple-
tion, two of these studies demonstrate concurrent
decreases in the expression of tyrosine hydroxylase, the
penultimate enzyme in dopamine synthesis [95,96]. The
mechanism controlling Ddc mRNA repression following
pyrethroid exposure is unclear, but provides support that
monoaminergic neurotransmitter systems are sensitive to
the compounds.
The changes in gene transcription observed in the present
study occur at doses at or near the threshold for eliciting
acute neurobehavioral signs of intoxication in the whole
animal [33,97,98]. Time course data (Figure 4) demon-
strate that transcriptional changes are transient and con-Page 18 of 23
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effects following acute, oral exposures observed in previ-
ous studies [97,99]. Currently, it is unclear if these tran-
sient gene expression changes are simply an adaptive
response of the nervous system to excitation by pyre-
throids, or whether they may contribute to development
of an adverse health effect. Regardless, these data demon-
strate alterations in gene transcription in cortex at low
doses of pyrethroids that produce only mild effects
observed in the whole animal.
Overall, increased expression of c-fos, Egr1 and Camk1g in
the present study are most likely regulated by pyrethroid-
induced changes in the neuronal firing patterns of cortical
neurons. The increased expression of Gpd1 and Fkbp51
mRNA indicates an indirect effect on glia due to non-spe-
cific activation of the HPA-axis.
Pyrethroid effects on branching morphogenesis
The SAFE analyses yielded an enrichment of the category
'morphogenesis of a branching structure' for both pyre-
throids. This was due to dose-dependent changes in
expression at 6 h for several genes that control neurite
branching and morphogenesis including Cxcl12, Notch1
and β-catenin [100-102]. A major function of this group
of genes is thought to involve the regulation of neuronal
morphogenesis during development. It is unknown
whether the same gene categories would show enrich-
ment at sampling times other than 6 h or whether these
transient changes in gene expression leads to a significant
change in neuronal morphology in the adult cortex.
Herein, we also report that both pyrethroids increased
neurite branch points in a developmental model of neur-
ite growth [58], but did not alter total neurite length (Fig-
ure 6). The gene expression data from the present study
are consistent with pyrethroid effects on neurite branch-
ing and not neurite length.
Overexpression of Notch1 in rat cortical neurons results in
an increase in neuronal branching and an antagonism of
neurite extension [100]. Likewise, overexpression of β-cat-
enin and Cxcl12 results in increased dendritic and axonal
branch tip number, respectively, and has no or opposite
effects on measures of length [101,102]. Transcripts for
these genes are upregulated following pyrethroid expo-
sure in the present microarray data (see Figure 5 heat-
maps) and suggest that pyrethroids affect the
developmental morphogenesis of neurons. However,
these data are not consistent with the results of two previ-
ous studies of pyrethroid effects on developmental neuro-
nal outgrowth. Treatment of developing X. laevis neurons
with 10 nM deltamethrin resulted in an increase in total
neurite length in the presence of extracellular Ca+2[103].
In contrast, exposure of N2A neuroblastoma or C6 glioma
cells to the pyrethroid cypermethrin resulted in no effect
on morphology [104]. The disparity between the results
from these studies and the present study may be due to
differences in the experimental conditions (cell types,
media, exposure durations, etc.), all of which are known
to impact neuronal outgrowth [105]. Preliminary experi-
ments in PC-12 neuroblastoma cells (data not shown) did
not demonstrate any effects on neurite branching or
length. The present data is the first to demonstrate an
effect of pyrethroids on the branching morphology of pri-
mary cultured neurons.
Disruption of neuronal morphogenesis in the developing
nervous system by pyrethroids could result in detrimental
effects on neurological function later in life. Intermittent
exposure to stimulant drugs such as amphetamine can
produce an increase in dendritic branching in vivo in both
juvenile and adult rats [106-108]. These morphological
changes are hypothesized to underlie some of the adverse
neurological effects associated with abuse of stimulant
drugs (e.g., learning deficits) [106,109]. In addition, lead
exposure during development results in neurological def-
icits that have been associated with changes in neuronal
morphology [110-112]. Both lead and stimulant drugs
facilitate neurite outgrowth in in vitro cell culture models
that is similar, but not identical, to the increased branch-
ing observed with pyrethroids in the present study [113-
117]. Several questions remain to be addressed before
definitive conclusions regarding pyrethroid effects on
neuronal morphogenesis can be made, including: 1)
whether or not pyrethroid-induced changes in morphol-
ogy occur in vivo, 2) are effects on morphogenesis specific
to cortical neurons, and 3) do all compounds in the pyre-
throid class produce the same types of effects on neuronal
branching morphogenesis?
Conclusion
The present study has identified a group of genes whose
transcription is altered in a dose-dependent manner in the
rat cortex following in vivo pyrethroid exposure. A major-
ity of the gene expression changes observed in this study
are consistent with the induction of neuronal hyperexcit-
ability by pyrethroids. The gene expression changes
observed are transient, comparable between the two pyre-
throids tested and provide insight into the cellular
response of the neurons downstream of the pharmacolog-
ical effects of these compounds at the neuronal mem-
brane. Most importantly, this study provides evidence
that branching of cortical neurons is increased by pyre-
throids, suggesting the neurotoxic action of these com-
pounds may include effects on neuronal morphology.
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calcium/calmodulin-dependent protein kinase I gamma;
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alpha B; Cxcl12: chemokine (C-X-C motif) ligand 12; Ddc:
dopa decarboxylase; Dusp6: dual specificity phosphatase
6; Dync1i1: dynein cytoplasmic 1 intermediate chain 1;
EDL: equipotent dose level; Egr1: early growth response 1;
Ets2: v-ets erythroblastosis virus E26 oncogene homolog
2; Fbxo22: F-box only protein 22; Finb: ras responsive ele-
ment binding protein 1 (predicted); Fkbp51: FK506 bind-
ing protein 5; GCOS: GeneChip® Operating Software;
Gna14: guanine nucleotide binding protein, alpha 14;
Gpd1: glycerol-3-phosphate dehydrogenase 1; Heatr1:
HEAT repeat containing 1 (predicted); HPA – hypotha-
lamic-pituitary-adrenal axis; Hsp27: heat shock 27 kDa
protein 1; Hyou1: hypoxia up-regulated 1; Igfpb3: insulin-
like growth factor binding protein 3; Klf4: Kruppel-like
factor 4; Klf10: Kruppel-like factor 10; Lrg1: leucine-rich
alpha-2-glycoprotein 1; Lpen2: lipin 2 (predicted); Max:
Max protein; Medl19: mediator of RNA polymerase II tran-
scription, subunit 19 homolog; mRNA: messenger ribo-
nucleic acid; Nedd4l: neural precursor cell expressed,
developmentally down-regulated 4-like; Nr4a3: nuclear
receptor subfamily 4, group A, member 3; Pde10a: phos-
phodiesterase 10A; Pdlm7: PDZ and LIM domain protein
7; PIR: penalized isotonic regression; Pld1 - phospholi-
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Slc39a8: solute carrier family 39 (zinc transporter), mem-
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A2 (predicted); Tcfcp2l1: transcription factor CP2-like 1;
Timp3: tissue inhibitor of metalloproteinase 3; Tmem10:
transmembrane protein 10; Usp54: ubiquitin specific
peptidase 54; Vdac1: voltage-dependent anion channel 1;
Wrnip1: Werner helicase interacting protein 1; Xdh: xan-
thine dehydrogenase; Zcch8: zinc finger, CCHC domain
containing 8 (predicted)
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